We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Liquid biopsy company ANGLE has announced that the US Food and Drug Administration has accepted its submission for substantive review of its Parsortix system for use with metastatic breast cancer (MBC) patients.